Skip to main content
H.R. 8454 117th Congress House

Medical Marijuana and Cannabidiol Research Expansion Act

Official title: To expand research on cannabidiol and marijuana, and for other purposes.

Introduced: July 22, 2022 See on congress.gov
Crime and Law Enforcement Alternative treatmentsCongressional oversightDrug safety, medical device, and laboratory regulationDrug therapy
More subjectsShow fewer subjects
Drug trafficking and controlled substancesDrug, alcohol, tobacco useHealth personnelLicensing and registrationsMedical researchPublic-private cooperationResearch administration and funding
Sign in to write a letter

Free account. One morning email at most, only on days something moved. Already have one? Sign in.

 Everywhere this bill has been 16 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 2, 2022
Became Public Law No: 117-215.
Dec 2, 2022
Signed by President.
Nov 29, 2022
Presented to President.
Nov 17, 2022
Message on Senate action sent to the House.
Nov 16, 2022
Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)
Nov 16, 2022
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
Jul 27, 2022
Received in the Senate, read twice.
Jul 26, 2022
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)
Jul 26, 2022
Motion to reconsider laid on the table Agreed to without objection.
Jul 26, 2022
Considered as unfinished business. (consideration: CR H7145-7146)
Jul 26, 2022
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Jul 26, 2022
DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.
Jul 26, 2022
Considered under suspension of the rules. (consideration: CR H7120-7124)
Jul 26, 2022
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Jul 21, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 21, 2022
Introduced in House
 Votes taken on this bill 1
DateChamberWhat was voted onResultYes–No
Jul 26, 2022 House · vote #392 On Motion to Suspend the Rules and Pass, as Amended Passed 325–95 See who voted →
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 2, 2022

Became Public Law No: 117-215.

 Plain-English summary Congressional Research Service

Medical Marijuana and Cannabidiol Research Expansion Act

This act establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the act includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
 Related & companion bills 1
  • S 253 Cannabidiol and Marihuana Research Expansion Act
 Bill text 5 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 10
All 10 Democratic 4 Republican 4
D
Cohen, Steve
Tennessee · Jul 22, 2022
 D
Dingell, Debbie
Michigan · Jul 22, 2022
Lee, Barbara
· Jul 22, 2022
 D
Pappas, Chris
New Hampshire · Jul 22, 2022
 R
Griffith, H. Morgan
Virginia · Jul 21, 2022
 R
Harris, Andy
Maryland · Jul 21, 2022
 R
Joyce, David P.
Ohio · Jul 21, 2022
 R
Mace, Nancy
South Carolina · Jul 21, 2022
 D
Norton, Eleanor Holmes
District of Columbia · Jul 21, 2022
Perlmutter, Ed
· Jul 21, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 8454: Medical Marijuana and Cannabidiol Research Expansion Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-8454/
MLA
"H.R. 8454: Medical Marijuana and Cannabidiol Research Expansion Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-8454/.
Bluebook (legal)
H.R. 8454, 117th Cong. (2026), https://openamerica.io/bill/117-HR-8454/.
Markdown link
[H.R. 8454: Medical Marijuana and Cannabidiol Research Expansion Act](https://openamerica.io/bill/117-HR-8454/)
Report a problem